# WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism

> **NCT03297359** · PHASE2 · TERMINATED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 92 (actual)

## Conditions studied

- Cancer
- Venous Thromboembolism
- Obesity

## Interventions

- **BIOLOGICAL:** Dalteparin

## Key facts

- **NCT ID:** NCT03297359
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-21
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-11-30
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** Low recruitment
- **Last updated:** 2024-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03297359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03297359, "WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03297359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*